Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma

Diffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogeneous disease. Despite good responses to standard of care frontline chemoimmunotherapy, the prognosis of relapsed/refractory (R/R) patients remains obscured by the possible inadequate responses to salvage therapy, eligibi...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Rita Assi, Nohad Masri, Iman Abou Dalle, Jean El-Cheikh, Hady Ghanem, Ali Bazarbachi
Formato:	Artigo
Idioma:	Inglês
Publicado em:	SAABRON PRESS 2021-03-01
coleção:	Clinical Hematology International
Assuntos:	DLBCL relapsed/refractory transplantation ADC polatuzumab vedotin
Acesso em linha:	https://www.atlantis-press.com/article/125953899/view
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!